{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-024560","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2026-06-09T11:30:04+00:00","discovered_at":"2026-06-09T11:35:00.254546+00:00","generated_at":"2026-06-09T11:36:19.490959+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kuva Labs delays tender offer for Lisata to June 10; outside date extended to July 17","bullets":["Tender offer commencement deadline extended from June 1 to June 10, 2026; company waives claims for previous delay.","Outside date extended from July 1 to July 17, 2026; Parent may pay $1.5M non-refundable fee to extend to August 17.","Parent acknowledges no committed financing; plans up to $25M in convertible notes from JBA Asset Management only non-binding.","Company waives $250K interim operating payment default in exchange for $150K on June 12 and $100K on June 26.","Lisata covenants not to sue until June 10; termination rights if Parent breaches."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-024560","json":"https://secwatch.observer/filing/0001140361-26-024560.json","markdown":"https://secwatch.observer/filing/0001140361-26-024560.md","text":"https://secwatch.observer/filing/0001140361-26-024560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000114036126024560/0001140361-26-024560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000114036126024560/ef20075787_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:36:19.490959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"083ecccde26717937ae43ea4ce9611aae80e5535","claim":"LISATA THERAPEUTICS, INC. amended Amendment and Waiver to Agreement and Plan of Merger with Kuva Labs Inc. valued at Amendment extends tender offer commencement date to June 10, 2026, extends Outside Date to July 17, (effective 2026-06-08).","evidence_excerpt":"On June 8, 2026, Lisata Therapeutics, Inc. (the \"Company\" or \"Lisata\") and Kuva Labs Inc., a Delaware corporation (\"Parent\"), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), entered into an amendment and waiver (the \"Amendment\") to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (as it may be amended from time to time, the \"Merger Agreement\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126024560/0001140361-26-024560-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Kuva Labs Inc."},{"label":"Value","value":"Amendment extends tender offer commencement date to June 10, 2026, extends Outside Date to July 17,"},{"label":"Effective","value":"2026-06-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}